Evidence map›Paper›PMID 32466621›Full record

ArticleCancers2020

Genetic Target Modulation Employing CRISPR/Cas9 Identifies Glyoxalase 1 as a Novel Molecular Determinant of Invasion and Metastasis in A375 Human Malignant Melanoma Cells In Vitro and In Vivo.

Jana Jandova, Jessica Perer, Anh Hua, Jeremy A Snell, Georg T Wondrak

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Deuterium Oxide (DCancers · 2021
    Article
  9. Review
  10. Glyoxalase System in the Progression of Skin Aging and Skin Malignancies.International journal of molecular sciences · 2020
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jana JandovaDepartment of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
Jessica PererDepartment of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
Anh HuaDepartment of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
Jeremy A SnellDepartment of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
Georg T WondrakDepartment of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA.ORCID 0000-0003-4799-8608
University of Arizona · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7M
Targeted Prevention for Non-Melanoma Skin CancerP01CA229112 · NCI · UNIVERSITY OF ARIZONA · PI MANSOUR, HEIDI M. · 2019 to 2023
$7.1M
Repurposing Clinical ACT Antimalarials for Experimental Melanoma InterventionR01CA229418 · NCI · UNIVERSITY OF ARIZONA · PI WONDRAK, GEORG T · 2019 to 2023
$1.7M
Exploring the role of HOCI in skin photodamage, immunosuppression, and carcinogenesisR21ES029579 · NIEHS · UNIVERSITY OF ARIZONA · PI WONDRAK, GEORG T · 2019 to 2020
$409k
Zinc dysregulation as a druggable target in human skin photocarcinogenesisR03CA230949 · NCI · UNIVERSITY OF ARIZONA · PI WONDRAK, GEORG T · 2018 to 2019
$147k
NCI NIH HHS P01 CA229112NCI NIH HHS R01 CA229418NCI NIH HHS R03 CA230949NIEHS NIH HHS P30 ES006694NIEHS NIH HHS R21 ES029579NIH HHS 1P01CA229112NIH HHS 1R01CA229418NIH HHS 1R03CA230949NIH HHS 1R21ES029579NIH HHS CA023074NIH HHS ES006694NIH HHS ES007091
6 · The paper itself

Abstract

Metabolic reprogramming is a molecular hallmark of cancer. Recently, we have reported the overexpression of glyoxalase 1 (encoded by

Indexed as

CMV-driven re-expressionCRISPR/Cas9epithelial–mesenchymal transitionglyoxalase 1malignant melanomamatrix metalloproteinase 9SCID mouse metastasis modeltranswell invasion

Identifiers

PMID32466621
PMCPMC7352620
OpenAlexW3032810379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.